Beta Bionics, Inc. Common Stock (BBNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beta Bionics, Inc. Common Stock (BBNX) has a cash flow conversion efficiency ratio of -0.030x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.73 Million) by net assets ($294.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beta Bionics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Beta Bionics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Beta Bionics, Inc. Common Stock balance sheet liabilities for a breakdown of total debt and financial obligations.
Beta Bionics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beta Bionics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kolon Life Science Inc
KQ:102940
|
0.007x |
|
Beijing Transtrue Technology Inc
SHE:002771
|
0.002x |
|
Dalian Zhiyun Automation Co Ltd
SHE:300097
|
0.049x |
|
China Datang Corporation Renewable Power Co. Limited
F:DT7
|
0.045x |
|
Binh Minh Plastics JSC
VN:BMP
|
-0.034x |
|
Hota Industrial Mfg. Co Ltd
TW:1536
|
0.026x |
|
Calavo Growers Inc
NASDAQ:CVGW
|
0.011x |
|
QUADIENT SA ADR1/15/EO 1
F:NEQ0
|
N/A |
Annual Cash Flow Conversion Efficiency for Beta Bionics, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Beta Bionics, Inc. Common Stock from 2022 to 2024. For the full company profile with market capitalisation and key ratios, see Beta Bionics, Inc. Common Stock stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $76.01 Million | $-48.27 Million | -0.635x | -14.72% |
| 2023-12-31 | $58.61 Million | $-32.45 Million | -0.554x | +88.05% |
| 2022-12-31 | $13.00 Million | $-60.21 Million | -4.631x | -- |
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch P… Read more